Radiation therapy used most often for prostate cancer regardless of decision-making factors
the ONA take:
The most common treatment for prostate cancer is radiation therapy, regardless of cancer stage, prostate-specific antigen (PSA) level, and prognosis and risk rating.
In an analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for 37,621 men with a prostate cancer diagnosis from 2004 to 2007, the researchers found radiation therapy was the most common treatment, followed by radical prostatectomy and other treatments including watchful waiting or active surveillance (WW-AS).
Radiation treatment was the most common regardless of stage, PSA level, and prognosis and tumor rating; however, PSA level influenced the choice of radical prostatectomy.
Clinical stage, as well as prognosis and tumor rating, influenced patients to choose WW-AS, but cancer stage, PSA level, and prognosis and risk rating prompted a decision to undergo androgen-deprivation therapy (ADT).
The authors reported that increased use of treatments in men with prostate cancer and underuse of active surveillance in men with low-risk disease remain.
Their study concludes that further research into what drives treatment choices among both patients and their physicians are needed.
Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|